Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa

Overview

Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary skin disease characterized by cutaneous and mucosa fragility. Blister formations and erosions, resulting in chronic wounds and dystrophic scars, lead development of aggressive cutaneous squamous cell carcinoma (cSCC) in young subjects. cSCC in RDEB patients are often recurrent and sometimes aggressive. Although fibrotic and inflammatory microenvironment plays an important role in the tumoral process, specific mechanisms in cSCC of RDEB patients are still unknown. Actually, the only treatment is a wide surgical excision with poor prognostic (80% of death after the first occurrence of cSCC). The objective of the study is to describe the molecular signatures in the cSCC in RDEB patients

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: December 2023

Arms, Groups and Cohorts

  • RDEB patients with a cSCC
  • Non-RDEB patients with a SCC induced by ultraviolet radiation
  • Healthy donors without RDEB nor SCC

Clinical Trial Outcome Measures

Primary Measures

  • Characterize the molecular signatures in the cSCC and the peri-tumoral dystrophic area occurring in RDEB patients
    • Time Frame: at inclusion
    • Molecular signatures will be assessed by genomic, transcriptomic, and proteomic analyses

Secondary Measures

  • Comparison of molecular signature according to the aggressive evolution
    • Time Frame: at inclusion
    • Molecular signatures will be assessed by genomic, transcriptomic, proteomic analyses and will be compared between RDEB patients with different clinical outcomes (cSCC with an aggressive and metastatic evolution versus cSCC without aggressive evolution at 3 months).
  • Comparison of molecular signatures between cSCC from RDEB patients versus cSCC from non-RDEB patients (induced by ultraviolet radiation)
    • Time Frame: at inclusion
    • Molecular signatures will be assessed by genomic, transcriptomic, and proteomic analyses and will be compared between cSCC from RDEB patients versus cSCC from non-RDEB patients (induced by ultraviolet radiation)

Participating in This Clinical Trial

Inclusion Criteria

  • for RDEB patients with a SCC : 1. aged older than 18 years old 2. one or more SCC surgically treated 3. signed genetic consent form – for non-RDEB patients with a SCC induced by ultraviolet radiation : 1. aged older than 18 years old 2. one or more SCC induced by ultraviolet radiation 3. signed genetic consent form Exclusion Criteria:

  • under protection by law (tutorship or curatorship) – without health insurance coverage

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Emmanuel BOURRAT, Dr, +33 1 42 49 90 90, emmanuelle.bourrat@aphp.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.